Alnylam has assembled a team of passionate leaders from the biopharmaceutical industry bringing together their collective experiences of drug discovery, drug development, and commercialization. All members of Management Board are also part of Operating Team.
Akin Akinc, Ph.D.
VP, General Manager, Hemophilia Program
Dr. Akinc joined Alnylam in 2003 and has served in roles of increasing responsibility and leadership in the research organization. During his time at Alnylam he has led the formulation group and has served as co-leader for interdisciplinary efforts focused on delivery of RNAi therapeutics and the development of RNAi platform technology. Akin has also contributed to Alnylam’s therapeutic programs, having served as Program Leader for multiple programs. He has led the fitusiran program from discovery to its current clinical stage. Akin received his B.S.E in Chemical Engineering from Princeton University and his Ph.D. in Chemical Engineering from the Massachusetts Institute of Technology.Close Bio
General Manager, France
Antoine leads the development of Alnylam’s operations in France, bringing 20 years of experience in the biopharmaceutical industry, with experience in market access, marketing, business development and management positions in several European countries. Prior to Alnylam, he headed the Rare Diseases unit of Shire France and held the position of Country Manager France and BeNeLux for Cubist Pharmaceuticals. He also set up subsidiaries in France, Italy, and Spain as Country Managing Director and Regional Director Southern Europe at Forest Laboratories managing the pricing & launching Cystic Fibrosis products. Antoine had several impactful roles at Stallergenes Greer, including Senior VP Business and Corporate Development. Previously, he acted as VP Global Marketing and Market Access and led the access and launch of Oralair in 27 EU countries. Antoine completed a Management Acceleration Program at INSEAD, a Finance Certificate from HEC and has a Diploma in Biotechnology/Biochemistry Engineering from Institut National des Sciences Appliquées de Lyon (INSA).Close Bio
VP, Supply Chain
Mr. Berreby joined Alnylam in 2016 as Vice President of Supply Chain. Before joining Alnylam, Patrick served as the Head of Clinical Supply Chain at Shire Pharmaceutical where he was responsible for the end to end supply chain of nearly 30 products in multiple therapeutic areas. Prior to this role, Patrick was responsible for both Clinical and Commercial Supplies for rare diseases at Shire HGT. During his tenure, he implemented and operated the supply chain infrastructure to launch commercial products around the world with operations in the US, Europe, Latin America and Japan, enabling Shire to reach patients in 50 countries. As part of Shire’s global expansion, Patrick was the architect of Shire’s partnership with DHL to build an integrated center of excellence for packaging, labeling and distribution for rare disease in Nijmegen, Netherlands. Before taking on this role, Patrick rebuilt the Material Management organization for Transkariotic Therapies (prior to acquisition by Shire) including warehouse operation, weigh and dispense, and material planning. He also helped implement the first ERP system for the company, leading to successful health authority audits. Prior to joining Transkariotic Therapies , Patrick was the Material Manager at Biopure Biopharmaceutical responsible for planning, logistics and warehouse operations of manufacturing sites in three different states, supporting the launch of their first commercial product and distribution of clinical supplies. Patrick earned a Bachelor of Science in Industrial Engineering from Tel Aviv University and an MBA from Babson College.Close Bio
VP, Information Technology
Mr. Bilotta joined Alnylam in 2015 as Vice President, Information Technology. Prior to Alnylam, Jim served as Vice President and Chief Information Officer at Synogeva Biopharma Corp where his responsibilities included leading the IT organization and providing the IT strategy necessary to prepare for commercial launch. Prior to his role at Synageva, he served as Vice Preseident and CIO for Alexion Pharmaceuticals where he lead the global IT function from 2004 through2014. Jim has extensive pharma IT experience and holds a BS and MBA from Southern Connecticut State University.Close Bio
Steve Bossone, Ph.D.
VP, Intellectual Property
Dr. Bossone joined Alnylam 2010 from Shire HGT with over 15 years of experience in the biotech industry. As a Senior Patent Attorney at Shire he provided licensing, acquisition and litigation support as well as strategic input into the life cycle management of several marketed products. Steve began his career at Millennium Pharmaceuticals as a Scientist in the oncology group and then at Millennium Biotherapeutics where he headed the transcript profiling group to support drug discovery initiatives. He transitioned to the Intellectual Property field with positions of increasing authority at Millennium, ToleRx, Serono and Shire. He received his PhD in Molecular Pathology from the lab of Dr. Kenneth Marcu at SUNY Stony Brook (NY) and subsequently worked as a Research Fellow in Medicine in the lab of Dr. Vikas Sukhatme at Harvard Medical School and Beth Israel Hospital. Steve received his JD from Suffolk University School of Law.
Al Boyle, Ph.D.
SVP, Technical Operations
Dr. Boyle joined Alnylam in 2015. Before joining Alnylam, Al served as Vice President of Global Technical Services at Alexion Pharmaceuticals where he was responsible for technology transfer and process oversight of cGMP manufacturing of clinical and commercial products. Prior to his most recent role, Al served as Vice President, Technical Operations in Switzerland and Ireland. He was responsible for leading an organization in Switzerland accountable for business, technical and quality oversight of drug substance, drug product and finished product contract manufacturing organizations. Al lead the relocation of this organization in support Alexion’s expansion into Ireland. He also established the new operations organization responsible for delivery of a brownfield drug product manufacturing facility and a greenfield labeling and packaging, warehousing, testing, and office complex. Prior to his expatriate experience, Al had management responsibilities for various functions at the Alexion manufacturing facility in Rhode Island. Prior to joining Alexion in 2009, Al spent over eight years with Bristol-Myers Squibb in Syracuse, NY. His activities included fermentation and biocatalysis development, technology transfer and commercial manufacturing support of biologics products. He has also spent time in the Research and Development functions of Celgene Corporation, Akzo-Nobel and Hercules Inc. Al obtained B.S. and M.S. degrees from the State University of New York College of Environmental Science and Forestry and a Ph.D. in Microbiology from Rutgers University.Close Bio
VP, Clinical Operations
Mr. Cehelsky joined Alnylam in 2005 as Director of Clinical Operations and has served in roles of increasing responsibility and leadership in the U.S. and UK clinical organizations since that time. Jeff has over 20 years of experience in strategic global drug development across Phases 1 through 4. Prior to joining Alnylam, Jeff worked as Associate Director of Clinical Operations at Millennium Pharmaceuticals for two years, where he managed global clinical programs and teams focused in the areas of acute setting cardiovascular disease and oncology. Before that, Jeff was at Alkermes from 1999 to 2003, where he managed the clinical operations group. Jeff received his Bachelor of Science degree in Pharmacy from the University of Rhode Island, and his Masters of Business Administration from Boston College.Close Bio
VP, Drug Safety & Pharmacovigilance
Dr. Adrian Dana came to Alnylam in 2014 from Genentech/Roche, where she was VP of Oncology Safety Science. Prior to that she spent 10 years at Merck in Clinical Safety and Risk Management where her responsibilities included risk management and pharmacovigilance for vaccines, infectious diseases and oncology products. During her time in industry she has contributed to the filings and ultimate approval for 9 new vaccines and drugs. She started her industry career in medical affairs at Wyeth. Adrian is a pediatric infectious diseases specialist and was in academic clinical practice prior to joining industry.Close Bio
Mary Beth DeLena
VP, Associate General Counsel
Ms. DeLena joined Alnylam in 2007 and has served in roles of increasing responsibility in the legal department since that time. She was formerly Vice President, Legal and Secretary at Praecis Pharmaceuticals, where she established and developed the company’s legal department, overseeing all corporate legal issues. Prior to that, she worked in the law offices of Skadden, Arps, Slate, Meagher & Flom LLP, where she represented public corporations in ongoing SEC compliance and counseled clients on securities law matters, corporate governance, mergers and acquisitions, and other general business matters. Mary Beth received her B.A. in English from Trinity College and her J.D. from Northeastern University School of Law.Close Bio
Kevin Fitzgerald, Ph.D.
Dr. Fitzgerald joined Alnylam in 2005 as Associate Director of Research and has served in roles of increasing responsibility and leadership since that time. His achievements at Alnylam include leadership of the company’s RNAi delivery efforts, resulting in two clinically validated modes of siRNA delivery. He has led multiple programs – including Alnylam’s PCSK9 program – from discovery through pre-clinical development, regulatory submissions, and early clinical development. Kevin was lead author and coauthor on Alnylam’s seminal papers in The Lancet and the New England Journal of Medicine, which demonstrated the effects of RNAi therapeutics in man. Prior to joining Alnylam, Kevin worked as a Senior Research Scientist and Group Leader at Bristol Myers Squibb, where he contributed to the development of multiple pharmaceutical products, in addition to managing several technology and drug development alliances. Kevin received his B.S. in Genetics from Cornell University and his Ph.D. in Molecular Biology from Princeton University. He completed his post-doctoral fellowship in oncology at Harvard Medical School.Close Bio
Pritesh Gandhi, PharmD
VP, Medical Affairs
Dr. Gandhi joined Alnylam in 2014, having previously served as Associate Vice President of Global Medical Affairs at Sanofi Oncology, where he spearheaded and executed on the global publication, medical education, and medical communication strategy. Prior to Sanofi, he worked as Regional Director of Medical Scientific Relations at Alexion Pharmaceuticals, where he managed efforts to bridge the gap between the science of eculizumab and the practice of medicine in the area of paroxysmal nocturnal hemoglobinuria (PNH). Preceding Alexion, he was at Millennium Pharmaceuticals, where he was the operational lead for the EVENT registry. Before joining the pharmaceutical industry, Pritesh held an academic appointment at Massachusetts College of Pharmacy as well as an adjunct position at The University of Massachusetts Medical School. At that time, he also practiced as Cardiovascular Pharmacotherapy Specialist at UMass Memorial Health Care. Pritesh received his B.S. in Pharmacy and his PharmD from the Massachusetts College of Pharmacy and Health Sciences. He completed a clinical residency at The University of Illinois Chicago, and is a Registered Pharmacist in the State of Illinois and the Commonwealth of Massachusetts.Close Bio
Global Head, Ethics and Compliance
Ms. Garcia joined Alnylam in 2016 as Global Head, Ethics and Compliance. Prior to joining Alnylam, she served as Compliance Officer at Biogen, leading the compliance programs for the US Commercial and the R&D/Medical groups. Nereyda also previously served as VP, Legal for PerkinElmer, leading the legal function for the company’s Life Sciences business unit, and as Chief Ethics Officer for Haemonetics Corporation. Nereyda began her career in private litigation at Sherin and Lodgen LLP. She received her A.B. in History from Brown University and her J.D. degree from Northeastern University School of Law.Close Bio
Jared A. Gollob, M.D.
VP, Clinical Research
Dr. Gollob joined Alnylam in 2007 and has worked across multiple programs within the clinical development organization, including serving in a program leadership role for the company’s ALN-TTR programs. Prior to Alnylam, he was an Associate Professor of Medicine and Director of the Biologic Therapy Program at Duke University Medical Center, with a secondary appointment as Associate Professor of Immunology. He was also concurrently Head of Hematology/Oncology at the Duke VA Medical Center. Jared received his A.B. and M.D. from Columbia University, and then completed his clinical training at Massachusetts General Hospital, Harvard Medical School, and the Dana-Farber Cancer Institute. Jared is a board certified Medical Oncologist with interests in tumor biology and development of new treatments for renal cell carcinoma and melanoma. Previously, he has advised Chiron, Schering-Plough, Bayer, and Novartis on their oncology programs.Close Bio
VP, Legal, Europe and Canada
Ms. Greco joined Alnylam in 2016 as Vice President Legal, Europe and Canada, based in Switzerland. Arianna brings over 15 years of international experience in the life science industry, and recognized expertise in market expansion strategies and the build-out of operations in EMEA. Prior to Alnylam, Arianna built and managed the EMEA Legal Function at PTC Therapeutics, InterMune and Onyx Pharmaceuticals, providing comprehensive legal and compliance guidance to the development and commercialization of innovative treatments for rare and neglected disorders. Before Onyx, Arianna was at Celgene for over 5 years as Director Senior Legal Advisor, where she advised the International Operations of the company as it rapidly grew from a one product company to one of the world’s leading biotechnology companies. Arianna was admitted to the Bar in 1999 and began her career as In-House Counsel of a public research institution and later as Life Science Practice Leader in a boutique Law Firm in Italy. She received her J.D. degree in Law and a Doctorate Degree in Medical Bioethics from the University of Genova (Italy).Close Bio
VP, General Manager, TTR Program
Mr. Green joined Alnylam in 2015, having most recently worked at Synageva BioPharma, where he was Vice President of Program and Alliance Management. In that role he was responsible for the oversight, management, and leadership of the company’s lead compound being developed as an enzyme replacement therapy for an ultra-orphan genetic disease. Prior to Synageva, he worked as Senior Director, Product Development and Program Management at Infinity Pharmaceuticals, where he developed the clinical and commercial product strategy and led the operational execution for the development of a small molecule product being investigated in non-small cell lung cancer. Before working at Infinity, he spent over eight years at Genzyme Corporation, where he served in roles of increasing responsibility in program and brand management for multiple commercial oncology products. Eric received his Bachelor of Science in Chemical Engineering from the University of Michigan, a Masters in Chemical Engineering from the Massachusetts Institute of Technology (MIT), and an MBA from the MIT Sloan School of Management.Close Bio
Thomas Hoock, Ph.D.
VP, ALN-CC5 Program Lead
Dr. Thomas Hoock (Tom) joined Alnylam in 2016 as Vice President and ALN-CC5 Program Lead. During his 18+ year career at Vertex Pharmaceuticals, he successfully led multiple pre-clinical projects to IND-ready status. As VP in Program in Portfolio Management & Co-Lead of the Immune Mediated Disease Area Team (IMIDAT), he led multiple clinical programs in Rheumatoid Arthritis, Epilepsy and Hepatitis C infection. He is a seasoned program leader & mentor able to create dynamic and productive team environments with significant experience in asset licensing and company/M&A evaluations. Tom earned his undergraduate degree in Biology from Indiana University, and completed his PhD and did his post-doctoral work in the Division of Medical Sciences and Graduate School of Arts and Science at Harvard University.Close Bio
Jae Kim, M.D.
VP, Clinical Development
Dr. Kim joined Alnylam in 2016. Prior to joining Alnylam, he served as Executive Director, Clinical Development at MyoKardia, Inc. Prior to MyoKardia, he held positions of increasing responsibility at Amgen, most recently as Global Development Leader in the Cardiovascular Therapeutic Area. Jae received his B.A. in Neurobiology Magna Cum Laude from Cornell University, and an M.D. from Cornell University Medical College. He completed his post-doctoral fellowship in genetics at Harvard Medical School and his clinical training in cardiovascular disease at the Brigham and Women’s Hospital and Massachusetts General Hospital. Jae is a board certified cardiologist and served on the Faculty of Medicine at Harvard Medical School and the Brigham and Women’s Hospital before joining industry.Close Bio
Marko Kozul, M.D.
Marko Kozul, M.D. comes to Alnylam from Leerink Partners where he served as a senior biotechnology analyst for 2 years. Prior to Leerink, he served as an analyst at ThinkEquity Partners for 2 years and Jefferies & Company for 5 years. Earlier in his career, he worked as the Research Director for Variant Medical Consulting Group and as a consultant for the Medical Referral Source, Inc. Marko earned a Bachelor of Science in Cellular and Molecular Biology from the University of Michigan and an M.D. from the School of Medicine at International University of the Health Sciences. He is a member of the American Medical Association, and the American Society of Clinical Oncology.Close Bio
VP, Facilities, Engineering & Real Estate
Mr. Kyranos joined Alnylam in 2016 as Vice President of Facilities, Engineering & Real Estate. Prior to joining Alnylam, John spent 11 years at Shire Pharmaceuticals in roles of increasing responsibly before ultimately serving as Global Group Vice President of Facilities, Engineering & Real Estate at Shire Pharmaceuticals, where he supported operations and projects for Corporate, Research & Development, Manufacturing and International Commercial functions. He was responsible for Facilities Operations at Transkaryotic Therapies Inc. which was acquired by Shire in 2005. He also previously held a variety of engineering management positions at Wyeth, American Home Products and Genetics Institute. John actively contributes to educational and mentoring programs for high school and college students and is a member of the Biotechnology Advisory Board at Bunker Hill Community College. He obtained a B.S. in Marine Engineering and M.S. in Facilities Management from Massachusetts Maritime Academy.Close Bio
Christine Regan Lindenboom
VP, Investor Relations & Communications
Christine Regan Lindenboom is Vice President of Investor Relations and Communications at Alnylam. Christine brings extensive communications experience from across the biotech and pharmaceutical industry; having worked in corporate, financial, product, R&D and internal communications disciplines. Christine joined Alnylam from Pfizer, Inc. where she held several senior communications roles, including; leading Worldwide Research and Development communications, building out the communications function for the Global Health and Value, and serving as a corporate spokesperson for litigation, issues and corporate brand initiatives. Prior to Pfizer, Christine spent 8 years at Amgen, where she held progressively more senior roles including leading the launch communications for Vectibix and Xgeva, as well as building a communications strategy for the company’s late state oncology therapeutics portfolio. Following that experience, Christine served as a top company spokesperson and led financial communications, including all M&A efforts for the organization. Prior to Amgen, Christine had worked for the healthcare agencies Fleishman-Hillard and Feinstein Kean, and started her career at Millennium Pharmaceuticals where she sat on the launch team for VELCADE. Christine received her B.A. from Northeastern University, and sits on the communications committee of PhRMA.Close Bio
Martin A. Maier, Ph.D.
Dr. Maier joined Alnylam in 2006 and has served in roles of increasing responsibility and leadership in the research organization, including head of RNA synthesis and co-lead of interdisciplinary research teams focused on delivery of RNAi therapeutics and RNAi platform technology. In these roles, Martin has contributed to the development of lipid nanoparticles and GalNAc conjugates, two clinically validated platforms for siRNA delivery, and the advancement of multiple programs to development. Prior to joining Alnylam, Martin worked for more than 7 years at Isis Pharmaceuticals, most recently as an Associate Director and Group Leader in the medicinal chemistry department. Martin’s more than 17 years of industrial experience, include a position as head of oligonucleotide production at Metabion GmbH in Martinsried, Germany. He is the author of 60 peer-reviewed scientific publications in the field of oligonucleotide therapeutics and inventor of 16 issued patents. Martin received his professional degree in Chemistry and his Ph.D. in Organic Chemistry at the University of Tübingen, Germany.Close Bio
General Manager, UK & Ireland
Brendan Martin joined Alnylam in 2016 as General Manager for UK & Ireland, leading the site in Maidenhead, UK. Prior to joining Alnylam, Brendan spent 14 years working for Genzyme in roles of increasing responsibility in Sales, Business Unit leadership, External Affairs & Market Access and ultimately as General Manager. Prior to Genzyme, Brendan worked as an Executive Search consultant servicing the needs of the Pharmaceutical Manufacturing sector in Ireland. In the 80s and 90s, Brendan worked in a clinical laboratory and spent 9 years progressing through Sales and Marketing roles in Australia with Boehringer Mannheim’s Diagnostic business. Brendan has maintained close associations with patient representative groups and was a co-founder of the Irish Platform for Patient Organisations, Science and Industry (IPPOSI). He holds a degree in Analytical Science from Dublin City University.Close Bio
Muthiah (Mano) Manoharan, Ph.D.
SVP, Drug Discovery
Dr. Manoharan joined Alnylam in 2003. He was the former Executive Director of Medicinal Chemistry at Isis Pharmaceuticals, Inc., a leading biotechnology company focused on nucleic acid-based therapeutics where he had a 12-year tenure. With a distinguished career as a world-leading nucleic acid and bioconjugate chemist, Mano is an author on over 130 publications and over 200 abstracts, as well as the inventor on over 115 issued U.S. patents. Prior to Isis Pharmaceuticals, he earned his Ph.D. in chemistry at the University of North Carolina-Chapel Hill and conducted post-doctoral work at Yale University and the University of Maryland.Close Bio
VP Finance & Treasurer
Mr. Mason joined Alnylam in 2005 as Corporate Controller, and has served in roles of increasing financial and operational responsibility since that time. Prior to Alnylam, Mike was at Praecis Pharmaceuticals for five years, most recently as Corporate Controller. He began his career in financial management at KPMG LLP in 1997 where he worked with a variety of public and private audit clients. Mike received his Masters of Business Administration from Babson College and his Bachelors of Business Administration from Stetson University. He is a Certified Public Accountant.Close Bio
VP, General Manager, Givosiran Program
Mr. Miller joined Alnylam in May 2016 with 20 years of experience in the biotechnology and pharmaceutical industry. Prior to joining Alnylam, he held a variety of general management and commercial leadership roles in the United States, Europe, and Canada. While with Alexion, Merck Serono, Boehringer Ingelheim, and Eli Lilly, he worked across many disease areas in Primary Care, Specialty Care, Oncology, and Rare Diseases. Jeff earned his Bachelor of Arts in Communications from the State University of New York at Oswego and his MBA from Boston University.Close Bio
Lubomir (Lubo) Nechev, Ph.D.
VP, Process Sciences
Dr. Nechev joined Alnylam in 2004 and has held roles of increasing responsibility in the process development organization during that time, including the development of manufacturing processes for Alnylam pipeline programs. Prior to joining Alnylam, Lubo worked in the process development department at Transgenomic, Inc., now Agilent Technologies. Before that, he was a scientist at Ribozyme Pharmaceuticals Inc., which became Sirna Therapeutics and was acquired by Merck & Co., Inc. in 2006. Lubo received his B.S., M.S., and Ph.D. in Chemistry from the St. Kliment Ohridski University in Sofia, Bulgaria. He conducted his postdoctoral training at Vanderbilt University in Nashville.Close Bio
Saraswathy (Sara) Nochur, Ph.D.
SVP, Regulatory Affairs
Dr. Saraswathy (Sara) Nochur joined Alnylam in 2006 as VP of Regulatory Affairs and was promoted to SVP of Regulatory Affairs in 2013. She also served as Head of Quality Assurance and was the Program Leader for two development programs at Alnylam. Dr. Nochur has 25 years of experience in the areas of product development and regulatory affairs including early and late stage clinical programs as well as drug and device experience. Prior to Alnylam, she held the position of Vice President, Regulatory Affairs at The Medicines Company. She also held senior positions at BioTrack, Inc. including Vice President, Product Development and Regulatory Affairs, and Chief Operating Officer. Dr. Nochur has served as organizing committee member for the FDA DIA Ogliotherapeutics conference since 2006. She has also been a speaker at industry conferences including DIA, TIDES and BIO. Dr. Nochur received her B.S. and M.S. degrees in Microbiology from the University of Bombay in India, and her Ph.D. in Biochemical Engineering at MIT.Close Bio
VP, Commercial Practice
Mr. Orth is Vice-President of Commercial Practice at Alnylam Pharmaceuticals. Andy brings deep experience in commercial operations, analytics and finance from across the biopharma industry. He joined Alnylam in 2016 following six years with Biogen – most recently as the Vice-President of Global Decision Support within Biogen’s Global Commercial Strategy function. Andy also held the role of Vice-President, US Commercial Effectiveness & Operations for Biogen’s US business as it grew from two to six products across multiple therapeutic areas. Prior to Biogen, he was an Executive Director with Russell Reynolds Associates. Previously, Andy also held the positions of Vice-President, Finance and Global Controller for Genzyme’s renal business and Director of Commercial Finance for Amgen’s U.S. inflammation business. Andy received his B.S. from the University of Wisconsin and his MBA from the Johnson Graduate School of Management at Cornell University.Close Bio
VP, Clinical Pharmacology, Bioanalysis & DMPK
Gabriel Robbie is Vice President of Clinical Pharmacology, Bioanalysis and DMPK at Alnylam. In this role, he is responsible for establishing and championing model based drug development to guide dose selection and overseeing bioanalysis capabilities at Alnylam.
Prior to joining Alnylam, Dr. Robbie spent ten years as Senior Director and site head for Clinical Pharmacology/DMPK, Bioanalysis and Clinical testing laboratory at MedImmune, Gaithersburg. His group was responsible for PK, PD and ADA assays and contributing to clinical trial design through identification of appropriate patient population, biomarkers, diagnostics and dosing regimens. Prior to MedImmune, he spent three years in clinical pharmacokinetics with AstraZeneca, Wilmington, Delaware. He also spent four years as clinical pharmacology reviewer and acting team leader, in the division of cardio-renal drug products, at the U.S. Food & Drug Administration’s Office of Clinical Pharmacology.
Dr. Robbie holds bachelor and master degrees in pharmaceutics from Bangalore University (India) and a doctorate degree in pharmacokinetics from the University of Illinois at Chicago.Close Bio
Dr. Sakhamuri joined Alnylam in 2016. Prior to joining Alnylam, Siva served as Executive Director, Global Technical Services at Alexion Pharmaceuticals where he was responsible for technology transfer, process and operations oversight of cGMP manufacturing of clinical and commercial products. Prior to Alexion, Siva worked for Sanofi-Pasteur Biologics as Director, Manufacturing and with Bristol Myers Squibb in a series of roles within their chemical process development and global biotechnology functions. He also held research positions at Korea Research Institute of Bioscience and Biotechnology, Hong Kong University of Science and Technology and Penn State University. Siva holds a Ph.D. in Chemical Engineering from the Indian Institute of Technology.Close Bio
Laura Sepp-Lorenzino, Ph.D.
Dr. Sepp-Lorenzino joined Alnylam in 2014. Before joining Alnylam, Dr. Sepp-Lorenzino spent 14 years at Merck & Co., having most recently served as Executive Director and Department Head, RNA Therapeutics Discovery Biology. In this role, she was responsible for identification and optimization of siRNAs and delivery vehicles, advancement of pre-clinical candidates, and development of an siRNA-conjugate platform to expand the repertoire of tissues accessible to in vivo siRNA delivery. Prior to RNAi, Laura worked in oncology drug discovery and development, having led the Cancer Research Department at Merck West Point, and having been an Assistant Lab Member at Memorial Sloan-Kettering Cancer Center. Laura received her Professional Degree in Biochemistry from the University of Buenos Aires, and her M.S. and Ph.D. in Biochemistry from New York University.Close Bio
VP, Program and Alliance Management
Mr. Shufrin joined Alnylam in 2009 as Director of Business Planning and Program Management and has served in roles of increasing responsibility since that time, including leading Alliance Management since 2012. During his time at Alnylam, Dan has served as the program manager across multiple programs, including Alnylam’s hemophilia program since its inception. Additionally, Dan has lead multiple key alliances with Novartis, GSK, the Medicines Company, Monsanto, Ascletis, and most recently Sanofi Genzyme ranging in scope from basic research to technology to multi-product. Prior to Alnylam, Dan worked at Wyeth (now Pfizer) in various operational roles, including heading up hemophilia commercial product supply for both the Factor VIII and Factor IX markets. Dan began his career at Praecis Pharmaceuticals, where he worked as a biochemist for over 5 years. Dan received his Bachelors of Science in Biomedical Engineering from Northwestern University and his Masters of Business Administration from the Kellogg School of Management.Close Bio
VP, Regulatory Affairs
Mr. Slugg joined Alnylam in 2016. Prior to joining Alnylam, he served as Vice President of Regulatory Affairs at ARIAD Pharmaceuticals. Prior to ARIAD, he served as Director of Regulatory Affairs at IPSEN, and in various roles in Quality Assurance and Development at ORA Clinical Research and Development. Andrew holds a BS in Biology from Bates College, a MS in Regulatory Affairs and Health Policy from The Massachusetts College of Pharmacy and Health Sciences, and an MBA from Babson College.Close Bio
Aria Tavana, Ph.D
VP, Quality Assurance
Dr. Tavana joined Alnylam in 2013. Before joining Alnylam, Dr. Tavana was Senior Director of Process Development and Manufacturing at Momenta Pharmaceuticals, where he was involved in the launch and commercial production of generic enoxaparin, an anticoagulant, as well as the maintenance of an uninterrupted production supply chain spanning China, Europe, and the U.S. In addition, he was involved in the development of candidate drugs for oncology and immunology indications. Prior to Momenta, Aria was at Biogen Idec, where he most recently served as Director of Quality Assurance & Quality Control. In that role he oversaw quality assurance of commercial and clinical product lines, including final drug disposition for human use. Aria joined Biogen in 1995 and held positions of increasing responsibility in process and technical development, supply chain operations, quality assurance, and quality control. Prior to joining Biogen, he was an engineer and project leader in Process Development at Novartis, where he developed chemical engineering unit operations for commercial production. Aria received his B.S. in Chemical Engineering from the University of California, Berkeley, and his Ph.D. in Chemical Engineering from the University of Arizona, Tucson.Close Bio